300 related articles for article (PubMed ID: 29980491)
1. Stage-based Variation in the Effect of Primary Tumor Side on All Stages of Colorectal Cancer Recurrence and Survival.
Lee MM; MacKinlay A; Semira C; Schieber C; Jimeno Yepes AJ; Lee B; Wong R; Hettiarachchige CKH; Gunn N; Tie J; Wong HL; Skinner I; Jones IT; Keck J; Kosmider S; Tran B; Field K; Gibbs P
Clin Colorectal Cancer; 2018 Sep; 17(3):e569-e577. PubMed ID: 29980491
[TBL] [Abstract][Full Text] [Related]
2. The efficacy of chemotherapy and operation in patients with colorectal neuroendocrine carcinoma.
Wu Z; Yu D; Zhao S; Gao P; Song Y; Sun Y; Chen X; Wang Z
J Surg Res; 2018 May; 225():54-67. PubMed ID: 29605035
[TBL] [Abstract][Full Text] [Related]
3. Impact of tumor deposits on the prognosis and chemotherapy efficacy in stage III colorectal cancer patients with different lymph node status: A retrospective cohort study in China.
Li X; An B; Zhao Q; Qi J; Wang W; Zhang D; Li Z; Qin C
Int J Surg; 2018 Aug; 56():188-194. PubMed ID: 29936197
[TBL] [Abstract][Full Text] [Related]
4. The prognostic implications of primary tumor location on recurrence in early-stage colorectal cancer with no associated risk factors.
Kang SI; Kim DW; Kwak Y; Lee HS; Kim MH; Kim MJ; Oh HK; Kang SB
Int J Colorectal Dis; 2018 Jun; 33(6):719-726. PubMed ID: 29594445
[TBL] [Abstract][Full Text] [Related]
5. Primary tumor location as a prognostic factor in metastatic colorectal cancer.
Loupakis F; Yang D; Yau L; Feng S; Cremolini C; Zhang W; Maus MK; Antoniotti C; Langer C; Scherer SJ; Müller T; Hurwitz HI; Saltz L; Falcone A; Lenz HJ
J Natl Cancer Inst; 2015 Mar; 107(3):. PubMed ID: 25713148
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of surgery and adjuvant therapy in older patients with colorectal cancer: a STROBE-compliant article.
Yang L; Ma Q; Yu YY; Wang C; Meng WJ; Adell G; Albertsson M; Arbman G; Jarlsfelt I; Peng ZH; Li Y; Zhou ZG; Sun XF
Medicine (Baltimore); 2014 Dec; 93(28):e266. PubMed ID: 25526455
[TBL] [Abstract][Full Text] [Related]
7. Impact of Primary Tumor Site on Bevacizumab Efficacy in Metastatic Colorectal Cancer.
Wong HL; Lee B; Field K; Lomax A; Tacey M; Shapiro J; McKendrick J; Zimet A; Yip D; Nott L; Jennens R; Richardson G; Tie J; Kosmider S; Parente P; Lim L; Cooray P; Tran B; Desai J; Wong R; Gibbs P
Clin Colorectal Cancer; 2016 Jun; 15(2):e9-e15. PubMed ID: 26968236
[TBL] [Abstract][Full Text] [Related]
8. Primary Tumor Location and Survival in the General Population With Metastatic Colorectal Cancer.
Ahmed S; Pahwa P; Le D; Chalchal H; Chandra-Kanthan S; Iqbal N; Fields A
Clin Colorectal Cancer; 2018 Jun; 17(2):e201-e206. PubMed ID: 29221688
[TBL] [Abstract][Full Text] [Related]
9. Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: a nationwide cohort study.
Chen KH; Shao YY; Chen HM; Lin YL; Lin ZZ; Lai MS; Cheng AL; Yeh KH
BMC Cancer; 2016 May; 16():327. PubMed ID: 27221731
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer.
Iinuma H; Watanabe T; Mimori K; Adachi M; Hayashi N; Tamura J; Matsuda K; Fukushima R; Okinaga K; Sasako M; Mori M
J Clin Oncol; 2011 Apr; 29(12):1547-55. PubMed ID: 21422427
[TBL] [Abstract][Full Text] [Related]
11. Advanced Mucinous Colorectal Cancer: Epidemiology, Prognosis and Efficacy of Chemotherapeutic Treatment.
Ott C; Gerken M; Hirsch D; Fest P; Fichtner-Feigl S; Munker S; Schnoy E; Stroszczynski C; Vogelhuber M; Herr W; Evert M; Reng M; Schlitt HJ; Klinkhammer-Schalke M; Teufel A
Digestion; 2018; 98(3):143-152. PubMed ID: 29870979
[TBL] [Abstract][Full Text] [Related]
12. Real-world Data for High-risk Stage II Colorectal Cancer - The Role of Tumor Side in the Adjuvant Setting.
Araujo CS; Venchiarutti Moniz CM; Bonadio RC; Watarai GY; Rojas J; Nogueira PVS; Martinez JK; Moraes PMG; Braghiroli MI; Sabbaga J; Hoff PM
Clin Colorectal Cancer; 2021 Jun; 20(2):e100-e108. PubMed ID: 33234431
[TBL] [Abstract][Full Text] [Related]
13. Lack of Caudal-Type Homeobox Transcription Factor 2 Expression as a Prognostic Biomarker in Metastatic Colorectal Cancer.
Zhang BY; Jones JC; Briggler AM; Hubbard JM; Kipp BR; Sargent DJ; Dixon JG; Grothey A
Clin Colorectal Cancer; 2017 Jun; 16(2):124-128. PubMed ID: 27726953
[TBL] [Abstract][Full Text] [Related]
14. A relationship to survival is seen by combining the factors of mismatch repair status, tumor location and age of onset in colorectal cancer patients.
Li P; Xiao Z; Braciak TA; Ou Q; Chen G; Oduncu FS
PLoS One; 2017; 12(3):e0172799. PubMed ID: 28253296
[TBL] [Abstract][Full Text] [Related]
15. Colorectal cancer survival: An analysis of patients with metastatic disease synchronous and metachronous with the primary tumor.
Kumar R; Price TJ; Beeke C; Jain K; Patel G; Padbury R; Young GP; Roder D; Townsend A; Bishnoi S; Karapetis CS
Clin Colorectal Cancer; 2014 Jun; 13(2):87-93. PubMed ID: 24373733
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Outcome and Prognostic Factors of Sporadic Colorectal Cancer in Young Patients: A Large Institutional-Based Retrospective Study.
Kim TJ; Kim ER; Hong SN; Chang DK; Kim YH
Medicine (Baltimore); 2016 May; 95(19):e3641. PubMed ID: 27175682
[TBL] [Abstract][Full Text] [Related]
17. LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer.
Stanisavljević L; Myklebust MP; Leh S; Dahl O
Acta Oncol; 2016 Dec; 55(12):1425-1433. PubMed ID: 27435662
[TBL] [Abstract][Full Text] [Related]
18. Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial.
Midgley RS; McConkey CC; Johnstone EC; Dunn JA; Smith JL; Grumett SA; Julier P; Iveson C; Yanagisawa Y; Warren B; Langman MJ; Kerr DJ
J Clin Oncol; 2010 Oct; 28(30):4575-80. PubMed ID: 20837956
[TBL] [Abstract][Full Text] [Related]
19. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
[TBL] [Abstract][Full Text] [Related]
20. Concomitant Administration of Proton Pump Inhibitors and Capecitabine is Associated With Increased Recurrence Risk in Early Stage Colorectal Cancer Patients.
Sun J; Ilich AI; Kim CA; Chu MP; Wong GG; Ghosh S; Danilak M; Mulder KE; Spratlin JL; Chambers CR; Sawyer MB
Clin Colorectal Cancer; 2016 Sep; 15(3):257-63. PubMed ID: 26803708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
